我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
Entheon Biomedical Corp is a biotechnology research and development company committed to treat addiction and substance use disorders.
相关临床试验
1
1 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
100.0%
暂无批准数据
- Entheon Biomedical Corp. terminated its definitive business combination agreement with Nutravisor Inc., ending a proposed reverse takeover transaction originally announced in January 2026. - The biotechnology company focused on addiction and substance use disorder treatments received a CAD $175,000 cash payment and CAD $175,000 in settlement shares from Nutravisor. - Trading in Entheon's common shares remains halted on the Canadian Securities Exchange, with the company promising updates on trading resumption in due course.
